The annual global market for cardiac biomarkers is forecast to reach US$3.39 billion by the year 2017. The market potential of cardiovascular biomarkers is driven by their precision in early detection of risks associated with cardiac diseases that constitute a leading cause of mortality in most developed countries. A major factor driving growth in the global cardiovascular biomarker market is the ability of these markers to make accurate prediction of heart failure in stable patients.
The annual global market for the brain natriuretic peptide assays (BNP, NT-proBNP) assays is the fastest growing market segment. Sales are estimated to reach the $1 billion figure by the end of 2012 and further projected to reach close to $2 billion in 2017. A novel multi-marker IVD test showing comparable sensitivity and specificity for the diagnosis and prognosis of cardiac damage as the established heart failure markers at competing price levels, has a major opportunity to capture a substantial part of heart failure biomarker market.